These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2908950)

  • 1. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience.
    Logothetis CJ; Dexeus FH; Chong C; Sella A; Ayala AG; Ro JY; Pilat S
    J Urol; 1989 Jan; 141(1):33-7. PubMed ID: 2908950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
    Logothetis CJ; Samuels ML; Ogden S; Dexeus FH; Swanson D; Johnson DE; von Eschenbach A
    J Urol; 1985 Sep; 134(3):460-4. PubMed ID: 2993671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors.
    Logothetis CJ; Samuels ML; Selig DE; Wallace S; Johnson DE
    Cancer Treat Rep; 1985 Jan; 69(1):33-8. PubMed ID: 2981619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial.
    Troner M; Birch R; Omura GA; Williams S
    J Urol; 1987 Apr; 137(4):660-2. PubMed ID: 3550148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy of bladder cancer: a preliminary report.
    Logothetis CJ; Johnson DE; Chong C; Dexeus FH; Ogden S; von Eschenbach A; Ayala A
    J Urol; 1988 Jun; 139(6):1207-11. PubMed ID: 3373589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
    Scher HI; Yagoda A; Herr HW; Sternberg CN; Bosl G; Morse MJ; Sogani PC; Watson RC; Dershaw DD; Reuter V
    J Urol; 1988 Mar; 139(3):470-4. PubMed ID: 3343728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: results and followup.
    Galetti TP; Pontes JE; Montie J; Medendorp SV; Bukowski R
    J Urol; 1989 Nov; 142(5):1211-4; discussion 1214-5. PubMed ID: 2810495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors.
    Schwartz S; Yagoda A; Natale RB; Watson RC; Whitmore WF; Lesser M
    J Urol; 1983 Oct; 130(4):681-4. PubMed ID: 6684180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy)].
    Tobisu K; Matsumoto K; Takai K; Kakizoe T
    Nihon Hinyokika Gakkai Zasshi; 1987 Feb; 78(2):327-34. PubMed ID: 3613336
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant treatment of stages T2 to T4 bladder cancer with cis-platinum, cyclophosphamide and doxorubicin.
    McCullough DL; Cooper RM; Yeaman LD; Loomer L; Woodruff RD; Boyce WH; Harrison LH; Assimos DG; Lynch DF
    J Urol; 1989 Apr; 141(4):849-52. PubMed ID: 2926878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
    Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Izumi T; Miyasaki Z; Ito N
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):985-93. PubMed ID: 2460657
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study.
    Al-Sarraf M; Frank J; Smith JA; O'Bryan RM; Costanzi JJ; Stephens RL; Caraveo J; Crawford ED
    Cancer Treat Rep; 1985 Feb; 69(2):189-94. PubMed ID: 2578880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [[Neoadjuvant chemotherapy (cisplatin, doxorubicin, cyclophosphamide) in the treatment of invasive urothelial tumors of the bladder. Preliminary results of a prospective study concerning 22 patients].
    Trifard F; Chrétien Y; Vallantin X; Collet C; Lachand AT; Dufour B
    Ann Urol (Paris); 1988; 22(3):216-9. PubMed ID: 3401004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-VAC versus CisCA--chemotherapy in the treatment of advanced bladder cancer.
    Heimbach D; Wirth M; Frohmüller H
    Urol Int; 1992; 48(2):157-61. PubMed ID: 1585511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
    Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
    Nishiyama T; Sasagawa T; Tanikawa T; Katayama Y; Kawakami Y; Tomita Y; Terunuma M; Kimura M; Sato S; Osawa T
    Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):352-7. PubMed ID: 1564837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.
    Tannock I; Gospodarowicz M; Connolly J; Jewett M
    J Urol; 1989 Aug; 142(2 Pt 1):289-92. PubMed ID: 2746745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.